¼¼°èÀÇ IPV ¹é½Å ½ÃÀå : ºÎ¹®º°, ±¹°¡ ¹× Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
IPV Vaccines Market, By Vaccine Type, By Age Group, By Distribution, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1514894
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 379 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,589,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,565,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,977,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

IPV ¹é½Å(IPV Vaccines) ½ÃÀå ±Ô¸ð´Â 2023³â 1¾ï 8,945¸¸ ´Þ·¯¿´À¸¸ç, 2024³âºÎÅÍ 2032³â±îÁö CAGR 8.3%·Î ÃßÀÌÇϸç È®´ë ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

IPV ¹é½Å ½ÃÀå-½ÃÀå ¿ªÇÐ

¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±Ý Áõ°¡´Â IPV ¹é½Å äÅÃÀ» ÃËÁø

¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±Ý Áõ°¡´Â IPV ¹é½Å äÅÃÀ» Å©°Ô µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â ¼¼°èº¸°Ç±â±¸(WHO)´Â ¹é½ÅÁ¢Á¾ °­È­·Î ¼¼°è ¼Ò¾Æ¸¶ºñ ȯÀÚ°¡ 90% °¨¼ÒÇß´Ù°í º¸°íÇß½À´Ï´Ù. °Ô´Ù°¡ ¹Ì±¹ Á¤ºÎ´Â 2021³â 2¾ï 3,700¸¸ ´Þ·¯¸¦ ¼Ò¾Æ¸¶ºñ ¹Ú¸ê Ȱµ¿¿¡ ÇÒ´çÇϰí IPV ¹é½ÅÀÇ º¸±Þ¿¡ Á¾»çÇÏ´Â ÀÚ¼¼¸¦ ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾öû³­ ÅõÀÚ´Â IPV ¹é½ÅÀÇ °¡¿ë¼º°ú °¡¿ë¼ºÀ» º¸ÀåÇÏ°í ±Ã±ØÀûÀ¸·Î ¿¹¹æ Á¢Á¾·üÀ» Çâ»ó½ÃŰ°í ¼¼°è ¼Ò¾Æ¸¶ºñ ¹Ú¸êÀÇ ¸ñÇ¥¸¦ Çö½Ç¿¡ °¡±õ°Ô ¸¸µå´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

IPV ¹é½Å ½ÃÀå-ÁÖ¿ä ÀλçÀÌÆ®

¿ì¸® ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ® ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 8.3%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹é½Å À¯Çüº°·Î IPV ¹é½ÅÀº 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸¿©ÁÙ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¬·ÉÃþº°·Î´Â 2023³â¿¡ ¼Ò¾Æ°ú°¡ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

À¯Å뺰·Î´Â 2023³â¿¡´Â °øÀû ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÌ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

IPV ¹é½Å ½ÃÀå-¼¼ºÐÈ­ ºÐ¼® :

¼¼°è IPV ¹é½Å ½ÃÀåÀº ¹é½Å À¯Çü, ¿¬·ÉÃþ, À¯Åë, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº ¹é½Å À¯Çü¿¡ ÀÇÇØ 2°¡Áö·Î ºÐ·ùµË´Ï´Ù : ºÒȰ¼ºÈ­ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Å(Inactivated Poliovirus Vaccine)°ú °æ±¸ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Å(Oral Poliovirus Vaccine)ÀÔ´Ï´Ù. ºÒȰ¼ºÈ­µÈ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Å ½ÃÀåÀº °æ±¸ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Åº¸´Ù ¾ÈÀü¼ºÀÌ ³ô°í, Á¤ºÎÀÇ °­·ÂÇÑ Áö¿ø°ú IPV ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À» ÅëÇØ ¼Ò¾Æ¸¶ºñ ¹Ú¸êÀ» ¸ñÇ¥·Î ÇÏ´Â ±¹Á¦ÀûÀÎ ³ë·ÂÀÌ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¿¬·ÉÃþº°·Î µÎ °¡Áö ¹üÁÖ·Î ºÐ·ùµË´Ï´Ù. ¼Ò¾Æ¿ë ¹× ¼ºÀοë. ¼Ò¾Æ°ú ºÐ¾ß°¡ °¡Àå ³ôÀº Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÇ·á Áöħ¿¡ µû¶ó Àǹ«È­µÇ°í Á¤ºÎ ¹× ±¹Á¦Àû ³ë·Â¿¡ ÀÇÇØ Áö¿øµÇ´Â ¾î¸° ½ÃÀý ¼Ò¾Æ¸¶ºñ¸¦ ¿¹¹æÇϱâÀ§ÇÑ ¼Ò¾Æ¸¦ ´ë»óÀ¸·Î ÇÑ ¼¼°è ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.

IPV ¹é½Å ½ÃÀå-Áö¿ªº° ÅëÂû·Â

ºÏ¹Ì¿¡¼­´Â Á¤ºÎÀÇ °­·ÂÇÑ Áö¿ø°ú °ß°íÇÑ °Ç°­ °ü¸® ½Ã½ºÅÛÀÌ IPV ¹é½ÅÀÇ ³ôÀº º¸±Þ·üÀ» º¸ÀåÇÕ´Ï´Ù. À¯·´Àº Á¾ÇÕÀûÀÎ ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥°ú À¯·´ ¹é½Å Çൿ °èȹ°ú °°Àº ÀÌ´Ï¼ÅÆ¼ºê¸¦ ¹è°æÀ¸·Î Å« Á¸Àç°¨À» º¸¿©ÁÝ´Ï´Ù. ¾Æ½Ã¾Æ ÅÂÆò¾ç, ƯÈ÷ Àεµ¿Í Áß±¹Àº Àα¸°¡ ¸¹°í WHO¿Í À¯´Ï¼¼ÇÁ °°Àº ±¹Á¦±â±¸¿Í Á¤ºÎ°¡ Àû±ØÀûÀ¸·Î ¼Ò¾Æ¸¶ºñ ¹Ú¸ê Ä·ÆäÀÎÀ» ÆîÄ¡°í Àֱ⠶§¹®¿¡ ±Þ¼ÓÈ÷ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¼Ò¾Æ¸¶ºñ À¯ÇàÀÌ °¡Àå ³ôÀº ¾ÆÇÁ¸®Ä«¿¡¼­´Â ÀÎÇÁ¶ó Á¦¾àÀ¸·Î ÀÎÇÑ °úÁ¦´Â ³²¾Æ ÀÖÀ¸¸ç ¼¼°è º¸°Ç±â±¸°¡ ÀÚ±ÝÀ» Á¦°øÇϰí IPV ¹é½Å ¹èÆ÷¿¡ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ³²¹Ì¿¡¼­´Â Áö¿ª ¿¹¹æ Á¢Á¾ ÃßÁø°ú °Ç°­ °ü¸® ¾×¼¼½º °³¼±ÀÌ ½ÃÀåÀÇ ²ÙÁØÇÑ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

IPV ¹é½Å ½ÃÀå-°æÀï ±¸µµ :

IPV ¹é½Å ½ÃÀåÀº Çõ½Å, Àü·«Àû Á¦ÈÞ, ±¤¹üÀ§ÇÑ À¯Åë¸ÁÀ» ÅëÇØ ½ÃÀå Á¡À¯À² È®´ë¸¦ ¸ñÇ¥·Î ÇÏ´Â ÁÖ¿ä Á¦¾à ±â¾÷ °£ÀÇ °Ý·ÄÇÑ °æÀïÀÌ Æ¯Â¡ÀÔ´Ï´Ù. Sanofi Pasteur, GlaxoSmithKline, Pfizer µî ´ëÇü Á¦¾à ±â¾÷ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß ´É·Â°ú ¼¼°èÀûÀÎ µµ´Þ¹üÀ§¸¦ Ȱ¿ëÇÏ¿© È¿°úÀûÀÌ°í ¾ÈÀüÇÑ IPV ¹é½ÅÀ» ½ÃÀå¿¡ ÅõÀÔÇϰí ÀÖ´Ù ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ´ë±Ô¸ð ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À» Áö¿øÇϱâ À§ÇØ Á¤ºÎ ±â°ü ¹× WHO ¹× À¯´Ï¼¼ÇÁ¿Í °°Àº ±¹Á¦ º¸°Ç±â±¸¿Í ÀÚÁÖ ÆÄÆ®³Ê½ÊÀ» ¸Î°í ÀÖ½À´Ï´Ù. ½ÅÈï±â¾÷°ú Áö¿ª Á¦Á¶¾÷üµµ ¼ö¿ä Áõ°¡¿Í Á¤ºÎ Áö¿ø Á¤Ã¥¿¡ ÈûÀÔ¾î ½ÃÀå¿¡ ÁøÃâÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ º¸Á¸¹æ¹ýÀÇ °³¼±À̳ª È¥ÇÕ¹é½ÅÀÇ °³¹ß µî ¹é½Å±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ °æÀïÀÌ °ÝÈ­µÇ°í ÀÖ¾î °¢»ç´Â Á¦°øÇÏ´Â Á¦Ç°ÀÇ Â÷º°È­¸¦ µµ¸ðÇØ ¼±Áø±¹¡¤°³¹ßµµ»ó±¹ ¾çÂÊ¿¡¼­ ÇÁ·¹Á𽺸¦ È®´ëÇÏ·Á°í Çϰí ÀÖ´Ù ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå IPV ¹é½Å ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå IPV ¹é½ÅÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå IPV ¹é½Å »ê¾÷ Á¶»ç

Á¦5Àå IPV ¹é½Å ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå IPV ¹é½Å ½ÃÀå »óȲ

Á¦7Àå IPV ¹é½Å ½ÃÀå-¹é½Å À¯Çüº°

Á¦8Àå IPV ¹é½Å ½ÃÀå-¿¬·ÉÃþº°

Á¦9Àå IPV ¹é½Å ½ÃÀå-À¯Å뺰

Á¦10Àå IPV ¹é½Å ½ÃÀå-ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå IPV ¹é½Å ½ÃÀå-Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼®-IPV ¹é½Å »ê¾÷

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

IPV Vaccines Market size was valued at USD 189.45 million in 2023, expanding at a CAGR of 8.3% from 2024 to 2032.

The IPV Vaccines Market, defined as the sector dedicated to inactivated poliovirus vaccines used for polio prevention, is experiencing growth driven by global immunization initiatives and increasing awareness of polio eradication. The robust government vaccination programs, support from organizations like WHO and UNICEF, and rising incidences of polio in certain regions are propelling the market demand. However, market growth is restrained by the high costs of vaccine development and distribution challenges in remote areas. Nonetheless, opportunities exist in the development of combination vaccines, advancements in vaccine storage and delivery technologies, and increasing investments in healthcare infrastructure in emerging economies.

IPV Vaccines Market- Market Dynamics

Increased Government Funding for Immunization Programs Fuels Adoption of IPV Vaccines

Increased government funding for immunization programs is significantly boosting the adoption of IPV vaccines, as evidenced by initiatives. For instance, in 2020, the World Health Organization (WHO) reported a 90% reduction in polio cases worldwide due to enhanced vaccination efforts. Additionally, the U.S. government allocated USD 237 million to polio eradication efforts in 2021, further emphasizing the commitment to widespread IPV vaccine distribution. These substantial investments are crucial in ensuring the availability and accessibility of IPV vaccines, ultimately driving higher immunization rates and bringing the goal of global polio eradication closer to reality.

IPV Vaccines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.3% over the forecast period (2024-2032)

Based on Vaccine Type segmentation, IPV vaccines were predicted to show maximum market share in the year 2023

Based on Age Group segmentation, Pediatrics was the leading type in 2023

Based on distribution segmentation, Public Vaccination Programs were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

IPV Vaccines Market- Segmentation Analysis:

The Global IPV vaccine market is segmented based on Vaccine Type, Age Group, Distribution, End-User, and Region.

The market is divided into two categories based on Vaccine Type: Inactivated Poliovirus Vaccine, and Oral Poliovirus Vaccine. The Inactivated Poliovirus Vaccine segment led the market, driven by its enhanced safety profile compared to the Oral Poliovirus Vaccine, alongside strong government support and international efforts aimed at polio eradication through IPV immunization programs.

The market is divided into two categories based on Age Group: Pediatrics, and Adults. The pediatrics segment holds the highest share, driven by global immunization programs targeting children to prevent polio from an early age, as mandated by healthcare guidelines and supported by extensive government and international initiatives.

IPV Vaccines Market- Geographical Insights

In North America, strong government support and robust healthcare systems ensure high adoption rates of IPV vaccines. Europe also demonstrates a significant market presence, driven by comprehensive immunization programs and initiatives like the European Vaccine Action Plan. Asia-Pacific, particularly India and China, represents a rapidly expanding segment due to large populations and aggressive polio eradication campaigns supported by both governments and international organizations like WHO and UNICEF. Africa, facing the highest polio prevalence, sees substantial efforts in IPV vaccine distribution funded by global health organizations, although challenges remain due to infrastructural limitations. Latin America shows steady market growth fueled by regional immunization drives and improving healthcare access.

IPV Vaccines Market- Competitive Landscape:

The IPV vaccine market is characterized by strong competition among leading pharmaceutical companies, each striving to enhance their market share through innovation, strategic alliances, and extensive distribution networks. Major players such as Sanofi Pasteur, GlaxoSmithKline, and Pfizer dominate the market, leveraging their extensive R&D capabilities and global reach to introduce effective and safe IPV vaccines. These companies frequently engage in partnerships with government bodies and global health organizations like WHO and UNICEF to support large-scale immunization programs. Emerging players and regional manufacturers are also entering the market, driven by increasing demand and supportive governmental policies. Additionally, advancements in vaccine technology, such as improved storage solutions and combination vaccines, are intensifying competition as companies seek to differentiate their offerings and expand their presence in both developed and developing regions.

Recent Developments:

In December 2023, Panacea Biotec launched EasyFourPol, a fully liquid pentavalent vaccine in India, safeguarding children against diphtheria, tetanus, pertussis, polio, and Haemophilus influenza type B infections.

In April 2024, The Business Standard announced India's capability to supply its entire IPV within 3-4 months, emphasizing the necessity of additional doses to sustain the nation's polio-free status. Sanofi and Serum Institute of India (SII) are identified as the primary IPV vaccine suppliers, with Sanofi contributing approximately 80% of the requirement.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL IPV VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Sanofi Pasteur

GlaxoSmithKline plc

Pfizer Inc.

Merck & Co., Inc.

Johnson & Johnson

Serum Institute of India Pvt. Ltd.

Bharat Biotech

Panacea Biotec Ltd.

Bio Farma

Sinovac Biotech Ltd.

Astellas Pharma Inc.

Sinopharm Group Co., Ltd.

Valneva SE

Innovax

LG Chem

PT Bio Farma (Persero)

Others

GLOBAL IPV VACCINES MARKET, BY VACCINE TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL IPV VACCINES MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

GLOBAL IPV VACCINES MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

GLOBAL IPV VACCINES MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL IPV VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. IPV Vaccines Market Overview

2. Executive Summary

3. IPV Vaccines Key Market Trends

4. IPV Vaccines Industry Study

5. IPV Vaccines Market: COVID-19 Impact Analysis

6. IPV Vaccines Market Landscape

7. IPV Vaccines Market - By Vaccine Type

8. IPV Vaccines Market - By Age Group

9. IPV Vaccines Market - By Distribution

10. IPV Vaccines Market - By End-User

11. IPV Vaccines Market- By Geography

12. Key Vendor Analysis- IPV Vaccines Industry

13. 360 Degree Analyst View

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â